Three analysts upgrade PharmaMar’s valuation following results from its anticancer drug

PharmaMar is experiencing an impressive revaluation. During the year, a pharmaceutical company in the continuous market managed to record an increase of 67%thanks in large part to the momentum gained this week from results of the company’s new cancer drug. The company is currently listed on levels not seen since June 2022higher 68 euros. News of the drug prompted several analysts to improve their valuation of the company, which rose by 48% of the firm’s target share price.

Eight research houses that monitor the drug company’s performance in the stock market have revised their estimates of the company over the past week, although only three of these firms made changes to their expectations regarding their target stock market price.. The analyst behind the biggest increase in PharmaMar’s price target is JB Capital expert Joaquin Garcia.

JB Capital maintained a share valuation of around €50 for this company throughout the year, which gradually rose to €58 over the course of the year, which it finally reached in its September review, accompanied by sign purchases. But after The publication of the results in one fell swoop raised the price of the pharmaceutical company’s title by 79%.. The firm puts PharmaMar’s target price at €102, which represents a 50% upside trend in the coming months.

Good results

On the other hand, from Bankinter the value of the company’s share increased to 80 euroswhich is 42% more than the 56 euros at which they previously valued the title. With this new price, they expect the stock market to rise another 17% in the coming months. Bank expert Pedro Echeguren assures that the main motivation is “positive and statistically significant overall survival and progression-free survival results in a clinical trial with Zepzelka plus Tecentriq combination for the treatment of small cell lung cancer“. This latest analysis of the product demonstrated its effectiveness in treating this cancer.

Echeguren reiterates that this “news is very positive as it significantly improves the prospects for final approval of Zepzelka as first-line treatmentThe analyst explains that “PharmaMar’s partner, Jazz Pharmaceutical, plans to submit to the FDA (U.S. Food and Drug Administration) and PharmaMar to the EMA (European Medicines Agency). , application for registration of the combination of Zepzelza and Tecentriq in the first half of 2025“, which is expected to significantly increase the company’s profits.

Although at the moment this medicine has already been approved in 16 territories of the world.The analyst believes momentum will build into 2025, making him even more positive on the company’s estimates, especially improving his “sales growth forecast between 2023 and 2028.” up to 13% from previous 10%because of the best expectations that Zepzelca offers.”

On the other hand, from RX Securities also They raise the target price for the pharmaceutical company to 80 euros, which represents an increase of 23% compared to the 65 euros at which they previously valued the shares of this company.